These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 25766629

  • 1. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S, Samala G, Renuka J, Sridevi JP, Yogeeswari P, Sriram D.
    Bioorg Med Chem; 2015 Apr 01; 23(7):1402-12. PubMed ID: 25766629
    [Abstract] [Full Text] [Related]

  • 2. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B, Suryadevara P, Renuka J, Sridevi JP, Yogeeswari P, Sriram D.
    Eur J Med Chem; 2015 Oct 20; 103():1-16. PubMed ID: 26318054
    [Abstract] [Full Text] [Related]

  • 3. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU, Kotagiri S, Janupally R, Suryadevara P, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D.
    Bioorg Med Chem; 2015 Feb 01; 23(3):588-601. PubMed ID: 25541204
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J, Reddy KI, Srihari K, Jeankumar VU, Shravan M, Sridevi JP, Yogeeswari P, Babu KS, Sriram D.
    Bioorg Med Chem; 2014 Sep 01; 22(17):4924-34. PubMed ID: 25129171
    [Abstract] [Full Text] [Related]

  • 5. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sheikh MG, Rane R, Basu R, Verma P, Sundaram A, Mukherjee K, de Sousa SM.
    J Biomol Screen; 2015 Feb 01; 20(2):265-74. PubMed ID: 25300873
    [Abstract] [Full Text] [Related]

  • 6. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K, Surana S, Jain P, Patel HM.
    Eur J Med Chem; 2016 Nov 29; 124():160-185. PubMed ID: 27569197
    [Abstract] [Full Text] [Related]

  • 7. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU, Reshma RS, Janupally R, Saxena S, Sridevi JP, Medapi B, Kulkarni P, Yogeeswari P, Sriram D.
    Org Biomol Chem; 2015 Feb 28; 13(8):2423-31. PubMed ID: 25569565
    [Abstract] [Full Text] [Related]

  • 8. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
    Reddy KI, Srihari K, Renuka J, Sree KS, Chuppala A, Jeankumar VU, Sridevi JP, Babu KS, Yogeeswari P, Sriram D.
    Bioorg Med Chem; 2014 Dec 01; 22(23):6552-6563. PubMed ID: 25456076
    [Abstract] [Full Text] [Related]

  • 9. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU, Renuka J, Santosh P, Soni V, Sridevi JP, Suryadevara P, Yogeeswari P, Sriram D.
    Eur J Med Chem; 2013 Dec 01; 70():143-53. PubMed ID: 24148991
    [Abstract] [Full Text] [Related]

  • 10. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M, Renuka J, Sridevi JP, Pedgaonkar GS, Asmitha V, Yogeeswari P, Sriram D.
    Int J Mycobacteriol; 2015 Jun 01; 4(2):104-15. PubMed ID: 26972878
    [Abstract] [Full Text] [Related]

  • 11. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
    Jeankumar VU, Renuka J, Kotagiri S, Saxena S, Kakan SS, Sridevi JP, Yellanki S, Kulkarni P, Yogeeswari P, Sriram D.
    ChemMedChem; 2014 Aug 01; 9(8):1850-9. PubMed ID: 24962352
    [Abstract] [Full Text] [Related]

  • 12. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
    Jeankumar VU, Reshma RS, Vats R, Janupally R, Saxena S, Yogeeswari P, Sriram D.
    Eur J Med Chem; 2016 Oct 21; 122():216-231. PubMed ID: 27371925
    [Abstract] [Full Text] [Related]

  • 13. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D, Aubry A, Yogeeswari P, Fisher LM.
    Bioorg Med Chem Lett; 2006 Jun 01; 16(11):2982-5. PubMed ID: 16554151
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
    Medapi B, Renuka J, Saxena S, Sridevi JP, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D.
    Bioorg Med Chem; 2015 May 01; 23(9):2062-78. PubMed ID: 25801151
    [Abstract] [Full Text] [Related]

  • 15. Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against Mycobacterium tuberculosis and Hit Validation by Biological Assays.
    Pakamwong B, Thongdee P, Kamsri B, Phusi N, Taveepanich S, Chayajarus K, Kamsri P, Punkvang A, Hannongbua S, Sangswan J, Suttisintong K, Sureram S, Kittakoop P, Hongmanee P, Santanirand P, Leanpolchareanchai J, Spencer J, Mulholland AJ, Pungpo P.
    J Chem Inf Model; 2024 Aug 12; 64(15):5991-6002. PubMed ID: 38993154
    [Abstract] [Full Text] [Related]

  • 16. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
    Jeankumar VU, Renuka J, Pulla VK, Soni V, Sridevi JP, Suryadevara P, Shravan M, Medishetti R, Kulkarni P, Yogeeswari P, Sriram D.
    Int J Antimicrob Agents; 2014 Mar 12; 43(3):269-78. PubMed ID: 24434114
    [Abstract] [Full Text] [Related]

  • 17. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
    Kashyap A, Singh PK, Silakari O.
    Tuberculosis (Edinb); 2018 Sep 12; 112():83-88. PubMed ID: 30205973
    [Abstract] [Full Text] [Related]

  • 18. Antimycobacterial activities of novel fluoroquinolones.
    Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V, Sriram D.
    Biomed Pharmacother; 2009 Jan 12; 63(1):27-35. PubMed ID: 18031974
    [Abstract] [Full Text] [Related]

  • 19. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
    Bobesh KA, Renuka J, Jeankumar VU, Shruti SK, Sridevi JP, Yogeeswari P, Sriram D.
    Eur J Med Chem; 2014 Oct 06; 85():593-604. PubMed ID: 25127151
    [Abstract] [Full Text] [Related]

  • 20. Design of novel quinoline-aminopiperidine derivatives as Mycobacterium tuberculosis (MTB) GyrB inhibitors: an in silico study.
    Wang J, Zhao C, Tu J, Yang H, Zhang X, Lv W, Zhai H.
    J Biomol Struct Dyn; 2019 Jul 06; 37(11):2913-2925. PubMed ID: 30044186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.